MANAGEMENT
Barbara S. Fox, Ph.D., Chief Executive Officer
Dr. Fox is an experienced entrepreneur and scientist. She was founder, President and Chief Scientific Officer of Recovery Pharmaceuticals, a company developing and marketing medications for the treatment of addiction. Prior to founding Recovery Pharmaceuticals in 1998, she was Vice President, Immunology at ImmuLogic Pharmaceutical Corp. She joined ImmuLogic in 1993, having served on the faculty of the University Maryland School of Medicine, Baltimore, as Associate Professor of Medicine with tenure in the Division of Rheumatology and Clinical Immunology, Dept. of Medicine. Dr. Fox received her BA in Chemistry from Bryn Mawr College and her Ph.D. in Chemistry from MIT. Dr. Fox trained as a post-doc in cellular immunology at the NIH.
David Poorvin, Ph.D., Chief Business Officer
Dr. Poorvin has over 30 years of experience in the pharmaceutical industry.
Most recently, Dr. Poorvin retired from Schering-Plough Corporation as Vice
President of Business Development where he negotiated licenses, joint
ventures and acquisitions of pharmaceutical products and research
technologies. At the time of his retirement, 70% of Schering-Plough’s
pharmaceutical sales were derived from third party products acquired during
his tenure. Prior to spending 14 years in Business Development, Dr. Poorvin
held positions of Director of Clinical Research at Schering-Plough and
Pfizer Pharmaceuticals. He was responsible for several NDA programs and
product approvals at both companies, including such drugs as Procardia and
Imdur. Poorvin started his career in the pharmaceutical industry at Lederle
Laboratories, were he directed pre-clinical research in the cardiovascular
area. Dr. Poorvin received his BA from Hunter College and completed his Ph.D.
and post-doctoral training at Rutgers University.
Anne B. Baia, CPA, MST, MBA, Chief Financial Officer
Anne Baia has over 20 years experience in accounting, finance, business development and strategic management. She has been involved in raising over $25M in venture equity and has led efforts to secure several debt facilities. Most recently Ms. Baia has served as a consultant providing interim CFO and COO services to a variety of venture-backed life science firms. Ms. Baia has held senior finance, operations, and business development positions at Descartes Therapeutics (VP, Finance &Administration), Mercury Therapeutics (CFO &V.P. Business Development), and Phylos (V.P., Finance &Administration and Managing Director, Phylos GmbH). Prior to Phylos, Ms. Baia worked in public accounting specializing in early stage technology-based companies. She holds a Bachelor of Science in Management (cum laude) and a MBA and a MST (high distinction) from Bentley Graduate School of Business. Ms. Baia is a Certified Public Accountant, a member of the American Institute of Certified Public Accountants, a member of BIO´s Business Advisory Board, and Chair of the Massachusetts Biotechnology Finance Committee.
Eileen F. Bostwick, Ph.D., Vice President Product Development
Eileen Bostwick is an expert in the development of oral antibody products. She was VP, R&D at GalaGen Inc., a company that was spun out of Land O´Lakes to develop pharmaceutical products from bovine milk and colostrum. At GalaGen, she led the R&D, regulatory and clinical efforts to advance these products to human clinical testing. She managed all aspects of the development process, including immunizations and colostrum collection, QC and evaluation of raw materials, coordination of bulk manufacturing and analysis, establishment of product and process specifications, validation of analytical methods, development of preclinical testing protocols and interactions with the USDA, CFSAN and FDA. Since leaving GalaGen, she has been a consultant and VP, R&D at BioBalance Corp. Dr. Bostwick holds a Ph.D. in Animal Physiology from the University of Minnesota.
